Pancaim

Pancreatic cancer AI for genomics and personalized Medicine

The central PANCAIM concept is to successfully exploit available genomic and clinical data to improve personalized medicine of pancreatic cancer. PANCAIM’s concept is unique as it integrates the whole spectrum of genomics with radiomics and pathomics, the three future pillars of personalized medicine. The integration of these three modalities is very challenging in the clinic, but also with AI. PANCAIM uses an explainable, data-efficient, twostaged AI approach. AI biomarkers transform the unimodal data domains into interpretable likelihoods of intermediate disease features. A second AI layer merges the biomarkers and responds with an integrated assessment of prognosis, prediction and monitoring of therapy response, to assist in clinical decision making.

PANCAIM builds on four key concepts of AI in Healthcare: data providers, clinical expertise, AI developers, and MedTech companies to connect to data and bring AI to healthcare. Data quantity and quality is the main factor for successful AI. Partners provide eleven Pan European repositories of almost 6000 patients that are open to ongoing accrual. SME Collective Minds builds the GDPR data platform that hosts the data and provides a trustable connection to healthcare for even more and sustainable data. SME The Hyve builds tooling to connect to more genomic repositories (EOSC Health). Six Pan European academic centers provide clinical expertise across all modalities and help realize a curated, high quality annotated data set. Partners also include expert AI healthcare researchers across all clinical modalities with a proven track record. Finally, Siemens Healthineers provides their AI expertise and tooling to bring AI into healthcare for clinical validation and swift clinical integration in 3000 health care institutes.

AMIRES was involved in the project’s preparatory phase and in the negotiations. Within the project it is responsible for administrative project management and for dissemination of results.

• Partners:
  • STICHTING KATHOLIEKE UNIVERSITEIT, Netherlands
  • KAROLINSKA INSTITUTET, Sweden
  • OSLO UNIVERSITETSSYKEHUS HF, Norway
  • FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III, Spain
  • UNIVERSITY OF GLASGOW, United Kingdom
  • COLLECTIVE MINDS RADIOLOGY AB, Sweden
  • SIEMENS HEALTHCARE GMBH, Germany
  • THE HYVE BV, Netherlands
  •  AMIRES, s.r.o., Czech Republic

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement № 101016851, project PANCAIM.